Lupin gets USD 25 million from AbbVie for meeting key product development milestone
The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers, the Mumbai-based drug maker said in a statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Hematology | Lymphoma | Pharmaceuticals | Translocation